Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 May 14, 2021
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update May 10, 2021
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico Apr 27, 2021
Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates Mar 9, 2021
Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update Mar 2, 2021
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia Jan 27, 2021